fashion -WSS

fashion

author：explore 2025-08-26 02:42:12 - browse：21

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： White House drug shortage group privately met with industry

entertainment

knowledge

WSS

Attacks on the drug industry will lead to fewer breakthroughs

Influencer to be charged after chaos erupts in New York City's Union Square

The CDC's new social media misinformation war

A cyberattack has disrupted hospitals and health care in several states

AI gets buy

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

leisure time

fashion

explore

ChatGPT in medicine: STAT answers readers' burning questions

Johnson & Johnson sued for allegedly overpaying for workers' drugs

At least 13 dead in Texas as scorching temps continue

OTC birth control: A brief history of over the counter pill design

In age of alternative facts, a scholarly course on calling out crap

Cano Health’s bankruptcy is a warning for Medicare Advantage

Malaria cases in Florida and Texas: Here’s what you need to know

Johnson & Johnson sued for allegedly overpaying for workers' drugs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Johnson & Johnson sued for allegedly overpaying for workers' drugs

explore

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Dramatically reducing cancer deaths requires the PASTEUR Act

340B reform proposal comes out of Senate working group

Global cancer cases to surge 77% by 2050, WHO report says

Readout LOUD: Venture capital, Gilead, and more M&A

Influencer to be charged after chaos erupts in New York City's Union Square

entertainment

entertainment

knowledge

explore